↑  Read the latest from the desks  ·  fresh intelligence, published daily✦Quiet reading✦No ads, ever

✦Corporate brand & media services✦Made in Virginia Beach since 1997✦

electroCore: Rotting at the dock (four or more warning signs)Rotting at the dock

electroCore $ECOR

Grew revenue 27.2% in FY2025 to $32 million, operating margin -41.1% against a 7.5% median for electromedical & electrotherapeutic apparatus, equity -9.2% of assets.

Last filing10-Q, 4 Nov 2026

Next year, 80%$29M–$66M
Growth, on the year27.2%
Operating margin−41.1%
Equity of assets−9.2%
Credibility63%
Track record5 of 5
Your call, sealedNext year’s revenue, your range. Sealed now, graded when the annual report lands.
Edgarette’s full reading · exposure, experience, soundness, credibility, range

🫧 Edgar looked up electroCore, Inc. ($ECOR). Last filing: 10-Q, 2026-11-04. 6 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2025-04-03.

🔖 Exposure: revenue $32.0M (FY2025), total debt $7.8M. Experience: revenue up 27.2% on the year, up 55.7% a year over 4 years; operating margin -41.1%, up from -48.3%. Soundness: equity -9.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $29.5M and $66.4M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $27.9M to $70.4M. A statistical range, not company guidance. Against peers (13 filers, $50M+ revenue, electromedical & electrotherapeutic apparatus): operating margin -41.1% against a 7.5% median; growth 27.2% against 8.3%.

Read from its own SEC filings · nothing written, nothing inferred

electroCore, Inc. against its own record and its peers
Operating marginPeer median 7.5%-41.1%Revenue, on the yearPeer median 8.3%27.2%Equity of assetsPeer median 47.0%-9.2%Gold tick: the median of 14–14 peers with $50M+ revenue in electromedical & electrotherapeutic apparatus

Speed and cash · fiscal 2025

Cash Compass⚡ Fast, cash not yet · growing fast, but little cash arriving so far
Inside viewTurns -25.6% of revenue into operating cash; revenue growing 55.1% a year over three years; no common dividend; liabilities exceed assets.
Outside viewAmong under $50M companies: 53rd percentile for cash, 84th for growth. cash growth

Both views must agree for a label · a description, not advice.

Cash flow (op · inv · fin · free)−$8M · $4M · $8M · −$8M
Investment book (cash · short · long)$7M · $5M · — · current ratio 1.38
Revenue swing · equity of assets12.4% · -9.2%

electroCore is growing faster than its size class, with steadier revenue. Its own audited SEC figures.

The figures, as filed

Fiscal year end2025-12-31
Revenue$32M
Revenue, on the year27.2%
Revenue, a year over the record55.7%
Operating margin−41.1%
Operating margin, prior year−48.3%
Net margin−43.6%
Research and developmentnot filed separately
Total debt$8M
Equity of assets−9.2%
Return on equity—
Payout of profit—
Dividend per share—
Earnings per share$-1.65
Book value per share$-201.46
Revenue per share$3776.02
Shares outstanding8,483
Audited years read5

Peers: the median of 13 filers with $50M+ revenue in electromedical & electrotherapeutic apparatus.

Classic signals · fiscal 2025Altman Z″ -36.67 distress zone 1968Piotroski F 3 of 9 middling 2000Beneish M -4.51 below the −1.78 line 1999Sloan accruals -29.5% earnings backed by cash 1996DuPont ROE -478.7% = margin -43.6% × turns 1.64 × leverage 6.71

What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →

Health HarborelectroCore sails as Rotting at the dock4 warning signs

Health watch · 12 monthsDirector or officer change

Versus peersoperating margin −41.1% vs a 7.5% median · revenue growth 27.2% vs 8.3% · cash beats 53% of its size class · growth beats 84% 13 electromedical & electrotherapeutic apparatus filers

Trend · last year to this▲operating margin −48.3% → −41.1% · ▲revenue $25.2M → $32.0M · 5-year revenue: $5.5M · $8.6M · $16.0M · $25.2M · $32.0M

See all 18 electromedical & electrotherapeutic apparatus companies on POPS4 sorted from the newest ship to the boat at the dock
#CompanyConditionOperating marginRevenue growthSales
1New shipElectromedELMDNew ship18.8%15.3%$73.8M
2New shipMedtronicMDTNew ship17.8%8.4%$36.4B
3Sound shipTransMedics GroupTMDXSound ship17.9%37.1%$605.5M
4Weathered boatVasoVASOWeathered boat−3.2%2.7%$89.1M
5Weathered boatAxogen, Inc.AXGNWeathered boat−3.5%20.2%$225.2M
6Weathered boatBioLife Solutions834365Weathered boat−17.3%28.9%$96.2M
7Weathered boatOutset MedicalOMWeathered boat−55.8%5.1%$119.5M
8Weathered boatVivani MedicalVANIWeathered boat——$0.0M
9Weathered boatEndra Life SciencesNDRAWeathered boat——$0.0M
10Old boatIridexIRIXOld boat−4.9%8.2%$52.7M
11Old boatPrecision Optics CorporationPOCIOld boat−11.1%65.2%$31.5M
12Old boatStereotaxisSTXSOld boat−68.3%20.3%$32.4M
13Old boatNuwellisNUWEOld boat−134.3%−5.4%$8.3M
14Old boatCapsovisionCVOld boat−188.3%15.3%$13.6M
15Old boatNexalin TechnologyNXLOld boat−2781.7%78.8%$0.3M
16Rotting at the dockAdm Tronics UnlimitedADMTRotting at the dock−4.8%4.7%$3.3M
17Rotting at the dockelectroCoreECOR · this companyRotting at the dock−41.1%27.2%$32.0M
18Rotting at the dockPositron POSCRotting at the dock−2275.1%−21.5%$0.5M

From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.

Tied up at the dock.

🌊 Visit the Bay →
The warning signs
  • Liabilities exceed assets (often from years of share buybacks, not always distress)
  • Operating cash flow was negative
  • Operating loss a margin of -41.1% in FY2025
  • Revenue is hard to predict its 80% range is ±39%

Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.

Brand success factors · calendar 2025

The Trillion Score: 573

Exponential Success Score

Built on over $200 trillion of sworn revenue, 13 years of data, 770,002 figures. Sealed by Edgarette.

How The Trillion Score works. We read eight measures of success from electroCore's own SEC filings and test each one against the public companies in its field, here surgical & medical instruments & apparatus. The longer and fuller the record, the more weight those results carry. A model built on past filings then turns them into the odds of thriving, which means outgrowing the field for three years without a severe decline. A score of 500 is about average, and every 100 points doubles the odds. Every company is ranked on this same scale.

What it says here. At 573, electroCore's odds of thriving come to 49%, against about 37% for the typical filer. It meets 4 of 5 success points.

573The Trillion Score
49%modeled odds of thriving over three years
HighFall Risk
#23 of 116rank in its field
#383 of 2,824rank across all filers

What the score means

The higher the score, the more often companies went on to thrive. At this level, about 44 of every 100 did.

31%Under 45035%450 to 49938%500 to 54944%550 to 599This company: 57357%600 and up

Share of companies that beat their field for three years with no severe decline, tested on 2019 to 2022 filings.

Fall Risk: High

Separate from the score, this asks what could go wrong: the odds of sales falling 30% or the filings stopping within three years. In the tests, about 41 of every 100 companies in the High band did. That is the group's history, not a forecast for this company.

MoneyIt burned about 26 cents of free cash on each sales dollar after paying for its plants and equipment. Its cash would cover that burn for about 0.9 years. It holds more cash than debt.cash negative over five years
SwingsEven in its worst years on record, sales still grew.24.1% a year
Filed eventsIn the last two years it told the SEC about 5 filings on leadership or auditor changes.5

The eight success points

PointWhat it meansPlace in field
SpeedSales grew faster than most of its field.95 of 100Met
SteadinessGrowth was strong for how much it swung, so it looks dependable.97 of 100Met
Price premiumIt keeps more of each sales dollar than most of its field.98 of 100Met
Margin stays above the fieldNot filed.
Moat half-lifeNot filed.
Brand spend yieldBrand spending returns less gross profit than for the leaders in its field.14 of 100Not yet
Learning curveCosts fell as a share of sales as it grew.98 of 100Met
Climb in the fieldNot filed.

Price premium $8M is the extra gross profit over a field-median margin. Momentum $10M is gross profit times growth above the field's pace.

The actuarial view

CredibilityWith 8 years of filings, the record earns 44% of the weight. The rest stays at the middle of the field.0.44
Severe decline, class AAbout 22 of every 100 companies with this many points fell 30% or stopped reporting within three years.21.8%
Actual vs expectedSales are 184% higher than if it had simply kept pace with its field.2.84

Top of its field: #1 SANUWAVE Health · #2 AVITA Medical · #3 TELA Bio · #4 Inspire Medical Systems · #5 Insulet

Ranked by The Trillion Score. See the method and score your own brand. Tested on 2019 to 2022 filings. Odds, class and Fall Risk figures are the experience of similar filers, not a forecast for this company. A statistical description of past filings, not a rating or advice.

Recent filings
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.

Try InstagramSpriteHokaDisneyGatoradee.l.f.

Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·

1 · Follow

Follow their filings

Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.

On Bluesky: follow Edgar & Edgarette.

2 · Price it

A new leader’s rebrand and launch

Priced live by the same engine as our estimator, from the catalogue at wholesale.

Price the printing · Open the full estimator

✦ Build the kit yourself
3 · Confirm

Check it with Jenny

Most buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.

Jenny Huang Goodman MPA MSc MHSA, Principal

Book a time info@pops4.com
Independence. Every range, flag and score on these boards is identical for everyone. Clients of POPS4 or Hako Shikin receive no different numbers, no earlier access and no say in what is published. The service lines shown beside each board describe work we do; they never change the data. For reviewers: Method · Terms of use · Status
Free · unsponsored · source-linked

Clean data. No ads. Not now, not later.

Nine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.

Every row is a filing.Straight from the company's own SEC document, linked. Nothing written, nothing inferred.
Nobody is watching you read.No ad trackers, no cookies from us. Our page counts are cookieless.
One email, one job.Watch a company and we hold that address for the alert alone. One tap ends it. Never shared, never passed on.
The house pays for this.Corporate event programs, corporate supplies and branded merchandise, since 1997. That is what funds the desks, under the house's own vendor standards.
Free to reuse with credit · CC BY 4.0 · how the boards are built
Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners.